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Abstract
Background: Development of Type 2 diabetes, like obesity, is promoted by a genetic predisposition. Although several
genetic variants have been identified they only account for a small proportion of risk. We have asked if genetic risk is
associated with abnormalities in storing excess lipids in the abdominal subcutaneous adipose tissue.
Methodology/Principal Findings: We recruited 164 lean and 500 overweight/obese individuals with or without a genetic
predisposition for Type 2 diabetes or obesity. Adipose cell size was measured in biopsies from the abdominal adipose tissue
as well as insulin sensitivity (HOMA index), HDL-cholesterol and Apo AI and Apo B. 166 additional non-obese individuals
with a genetic predisposition for Type 2 diabetes underwent a euglycemic hyperinsulinemic clamp to measure insulin
sensitivity. Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, was associated with inappropriate
expansion of the adipose cells, reduced insulin sensitivity and a more proatherogenic lipid profile in non-obese individuals.
However, obesity per se induced a similar expansion of adipose cells and dysmetabolic state irrespective of genetic
predisposition.
Conclusions/Significance: Genetic predisposition for Type 2 diabetes, but not obesity, is associated with an impaired ability
to recruit new adipose cells to store excess lipids in the subcutaneous adipose tissue, thereby promoting ectopic lipid
deposition. This becomes particularly evident in non-obese individuals since obesity per se promotes a dysmetabolic state
irrespective of genetic predisposition. These results identify a novel susceptibility factor making individuals with a genetic
predisposition for Type 2 diabetes particularly sensitive to the environment and caloric excess.
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Introduction
Type 2 diabetes is undergoing a global epidemic mainly driven
by a concomitant epidemic in obesity [1]. The expanded adipose
tissue mass in obesity promotes insulin resistance which, in turn,
induces Type 2 diabetes in genetically susceptible individuals [2,3].
It is also well-established that a preponderance of (intra)abdominal
fat accumulation, estimated by an expanded waist or waist/hip
circumference ratio, is a better marker of the obesity-associated
complications, including the Metabolic Syndrome and cardiovas-
cular disease than obesity per se [3,4].
Accumulation of excess lipids in the adipose tissue can, in
principle, be induced by an expansion of the number of
differentiated adipose cells (hyperplastic obesity) and/or by
adipose cell enlargement (hypertrophic obesity) [5,6]. As a group,
obese individuals have larger fat cells than non-obese [5,6] and it
has long been known that hypertrophic, rather than hyperplastic,
obesity is closely associated with insulin resistance and the various
aspects of the Metabolic Syndrome [5,6] Interestingly, Spalding et
al. [7] recently showed that the number of abdominal subcuta-
neous adipose cells becomes established around puberty and that
adipose cell expansion becomes the predominant event for
subsequent fat accumulation. However, adult women may still
recruit new cells in the femoral/gluteal depot which appears to
counteract abdominal adipocyte accumulation [8] and this may
contribute to the well-established finding that peripheral (gluteo-
femoral) obesity is less harmful than abdominal obesity [5,6].
In order to differentiate between hypertrophic and hyperplastic
obesity, Arner et al. [6] conceived the delta-factor as a quantitative
statistical marker of inappropriate cell enlargement in relation to
amount of body fat. A positive value indicates that fat cells are
larger than expected from their body fat mass while a negative
value indicates the opposite.
A major reason for the association between insulin resistance
and abdominal adipose cell hypertrophy is probably the
dysregulated adipose tissue with local insulin resistance, altered
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local infiltration of inflammatory cells which inhibits normal
adipogenesis and differentiation of preadipocytes [9–12]. Other
markers of the dysregulated adipose tissue include reduced levels
of insulin signaling and action proteins like IRS-1 and GLUT4
protein in the abdominal adipose cells. This was initially described
in patients with Type 2 diabetes [13,14], but is now well
established to precede the development of Type 2 diabetes and
to be associated with insulin resistance and a dysmetabolic state
also in non-obese individuals [10,11,15]. Interestingly, a dysreg-
ulated adipose tissue with inappropriate hypertrophy of the
abdominal adipose cells was seen around four-times more
commonly in individuals with a genetic predisposition for Type
2 diabetes [10,11].
In the present study, we have measured adipose cell size, body
fat and metabolic variables in a large group of individuals with or
without a known genetic predisposition for overweight/obesity or
Type 2 diabetes. The results clearly demonstrate that genetic
predisposition for Type 2 diabetes, but not for overweight or
obesity, is associated with inappropriate abdominal adipose cell
enlargement in relation to amount of body fat. This becomes
particularly evident in non-obese individuals since obesity per se
promotes adipocyte expansion, and is associated with insulin
resistance and its consequences. Thus, genetic predisposition for
Type 2 diabetes is associated with adipose tissue dysfunction and
insulin resistance long before obesity develops and indicates that
this can be a major genetic susceptibility factor enhancing the
negative effects of the environment and body fat increase.
Materials and Methods
Subjects
166 individuals with at least one known first-degree relative with
Type 2 diabetes were recruited in Gothenburg and phenotyped as
described [16]. In addition, 83 subjects with a genetic predispo-
sition for Type 2 diabetes (first-degree relatives) were recruited in
Stockholm. Leanness was defined as body mass index
(BMI),25 kg/m
2. Seventeen of these individuals were lean and
66 overweight or obese (Table 1). In addition, 253 individuals with
heredity for overweight/obesity (also first-degree relatives) were
recruited; 56 of these were lean and 197 were overweight/obese
when included. 91 lean and 237 overweight or obese individuals
without any known genetic predisposition for these conditions
were included for comparison (Table 1). Family history for
overweight/obesity or Type 2 diabetes was determined as
described [17].
Ethics statements
The studies were approved by the local Ethical Committees at
the Sahlgrenska Academy and the Karolinska Institute and were
performed in agreement with the Declaration of Helsinki. All
subjects received written information and gave written consents to
participate.
Methods
Adipose tissue biopsies were obtained from the abdominal
subcutaneous adipose tissue around the umbilicus. Following
careful dissection, the adipose cells were digested with collagenase
and cell size measured with an ocular as previously reported [6,12].
The methods used in the laboratories of Stockholm and Gothen-
burg were carefully compared and validated as similar. However, to
exclude any bias, the effect of the genetic background on cell size
was only evaluated in the Stockholm cohorts (Table 1). The delta-
values were calculated [6]asthese valuesof adipose morphology are
independent of body fat mass. The values are quantitative, i.e., a
large negative value indicates pronounced hyperplasia and a large
positive value indicates pronounced hypertrophy [6]. The unad-
justed mean average fat cell volume in each individual was also
investigated and related to the amount of body fat. All subjects
underwent bioimpedance measurements of body composition and
waist circumferencewasmeasured[5,6]. Bloodsamples weredrawn
for measurements of fasting lipids, glucose and insulin levels as
reported [6,16] and HOMA index, which is an indirect measure of
insulin sensitivity, was calculated [18]. Euglycemic hyperinsulin-
emic glucose clamps were performed in the Gothenburg co-hort
comprising 166 individualswithknown heredityfor Type 2 diabetes
as previously reported [16] and the results were related to average
abdominal cell volume or the delta-values.
Statistical analysis
Significances of differences were calculated with unpaired t-test
and conventional methods were used to calculate means 6
standard error of mean (SE). Analysis of co-variance (ANCOVA)
was used to analyse statistical significance of cell volume
differences of subjects with or without a heredity for Type 2
diabetes or overweight/obesity.
Results
Fat cell size in relation to body fat
As shown in Figure 1A for all investigated subjects with/without
a known genetic predisposition for Type 2 diabetes, several lean
individuals with a known genetic predisposition for Type 2
diabetes showed a marked increase in abdominal fat cell volume
over a small increase in body fat as compared with lean subjects
without diabetes heredity. When lean subjects (BMI,25 kg/m
2)
were analyzed separately this influence of diabetes heredity was
significant by ANCOVA (Figure 1C) (F=5.8; p=0.019). In
contrast, in the whole sample as well as in a separate analysis, lean
individuals with heredity for overweight/obesity had the same
relationship between fat cell volume and fat mass as lean subjects
without such heredity (Figure 1B and 1D) (F=0.04 NS). Thus, a
known genetic predisposition for Type 2 diabetes, but not for a
high BMI, leads to inappropriately enlarged fat cells even when
the subjects are considered lean. In fact, many lean individuals
with a diabetes heredity can from the point of view of their fat cell
size be considered as obese.
Phenotypic characterization
We also examined abdominal adipose cell size in relation to
insulin sensitivity measured with a euglycemic clamp in the
Gothenburg group of 166 non-obese individuals (BMI,28 kg/m
2)
with a known genetic predisposition for Type 2 diabetes. As shown
in Figure 2, fat cell sizes which are considered within the normal
range in individuals lacking a diabetes heredity (,800 pl, which
was upper limit for lean with no diabetes heredity in Figure 1A)
were associated with a gradual reduction in insulin sensitivity. This
was also true when the relationship between insulin sensitivity and
inappropriately enlarged fat cells (for a given BMI) was expressed
as the delta-values (Figure 2B). These results are also consistent
with the concept that lean individuals with diabetes heredity
exhibit an ‘‘obese’’ phenotype with inappropriately enlarged fat
cells associated with a reduced insulin sensitivity.
We further verified the results by comparing HOMA-derived
insulin sensitivity and different metabolic variables in lean and
obese individuals with or without a genetic predisposition for Type
2 diabetes or overweight/obesity (Table 1). Individuals with a
genetic predisposition to Type 2 diabetes again showed a reduced
Restricted Adipogenesis in Type 2 Diabetes
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compared to the individuals lacking heredity for diabetes (larger
waist circumference, lower HDL-cholesterol, higher Apo B and
Apo B/Apo A1 ratios) (Table 1). Consistent with the results in
Figure 1A, the delta-value as a marker of inappropriate cell
enlargement, was also significantly increased in non-obese
individuals with heredity for Type 2 diabetes (p=0.01). Further-
more, the average unadjusted fat cell volume was increased in
those with a diabetes heredity in spite of no difference in fat mass
or BMI compared to these with a genetic predisposition for
overweight/obesity.
We also extended the analysis to include individuals with a BMI
up to 27 kg/m
2. However, essentially the same results were found
since heredity for Type 2 diabetes was again associated with larger
adipose cells when compared to matched subjects lacking a known
genetic predisposition or having heredity for obesity (adipose cell
size 506642 pL vs 410 pL, p,0.05). Similarly, the delta-value
was significantly higher in the subjects with a diabetes heredity
(p,0.01). These results further corroborate the concept that
genetic predisposition for Type 2 diabetes is associated with an
impaired ability to recruit preadipocytes to store excess fat in the
subcutaneous adipose tissue. This becomes most prominent in
non-obese individuals since obesity per se promotes adipose cell
expansion towards an upper maximal level.
We further validated that this difference was specifically related
to a genetic predisposition for Type 2 diabetes and not for
overweight or obesity. Individuals with a genetic predisposition for
a high BMI showed no evidence of an inappropriate expansion of
cell size in relation to amount of body fat measured as delta-value
(Table 1). In addition, heredity for a high BMI was not associated
with an adverse insulin-metabolic phenotype in lean individuals in
contrast to those with a diabetes heredity. Taken together, these
results show that a genetic predisposition for Type 2 diabetes, but
not for a high BMI, is associated with an ‘‘obese’’ phenotype in
lean individuals and they also exhibit a more pro-atherogenic
metabolic profile. However, obesity per se promotes both adipose
cell expansion and a dysmetabolic state to a similar extent
irrespective of heredity for Type 2 diabetes or overweight/obesity.
Discussion
These results show that a genetic predisposition for Type 2
diabetes in non-obese individuals is associated with inappropriate
expansion of the abdominal adipose cells for small increases in body
fat. Thus, they assume an ‘‘obese’’ phenotype long before the
conventional definition of overweight orobesity. Incontrast, genetic
predisposition for a high BMI, although promoting an obese
phenotype, is not associated with inappropriate abdominal adipose
cell enlargement in relation to amount of body fat when measured
asabsolutesize ordelta-values.Insulinsensitivityisalso reduced and
negatively correlated to adipose cell size in non-obese subjects with
heredityforType 2diabetes.Takentogether,thesedatasuggestthat
a genetic predisposition for Type 2 diabetes is associated with an
impaired ability to recruit and/or differentiate new adipose cells to
store excessive lipids. This finding is consistent with our previous
results that diabetes heredity in non-obese subjects is frequently
associated with markers of a dysregulated adipose tissue, inappro-
priate adipose cell hypertrophy and reduced circulating adiponectin
levels [10,11]. Also other markers of a dysregulated adipose tissue,
including markers of terminal cell differentiation and PPARc-
regulated genes such as adiponectin and GLUT4, are commonly
reducedintheabdominaladiposetissueinindividualswithagenetic
predisposition for Type 2 diabetes [10,11,15]. The concept of an
impaired recruitment of new and functional adipose cells in
individuals with a genetic predisposition for Type 2 diabetes,
leading to inappropriately enlarged abdominal adipose cells, is
Table 1. Comparison of lean and overweight individuals with or without a genetic predisposition for type 2 diabetes or
overweight/obesity.
Lean individuals Overweight or obese individuals
Genetic predisposition Genetic predisposition
Type 2 diabetes Overweight or obesity Type 2 diabetes Overweight or obesity
Measure
Yes
(n=17)
No
(n=65)
Yes
(n=56)
No
(n=26)
Yes
(n=66)
No
(n=184)
Yes
(n=197)
No
(n=53)
Age, years 38623 3 613 5 613 2 614 0 614 0 614 0 613 8 61
Waist circumference, cm 8262(*) 79618 0 61* 77611 1 7 621 1 4 611 1 6 61*** 10762
BMI, kg/m
2 22.960.4 22.460.2 22.760.2 22.260.3 40.060.8* 37.060.5 38.360.4*** 34.460.9
Body fat mass, kg 19611 8 611 8 611 7 616 1 625 6 616 0 61*** 4863
Fat cell volume, pL 511645** 400619 431623 407630 824621 806614 827612** 739629
Delta value, pL 64638** 237618 215621 218628 9617 22611 21611 13621
HOMA, index 1.6260.24* 1.1760.08 1.2660.09 1.2660.16 3.760.2 3.760.2 3.860.2 3.260.4
P-HDL cholesterol, mM 1.3960.10* 1.6260.05 1.5660.07 1.6060.07 1.1760.05 1.2060.02 1.1960.02 1.2660.05
P-Apo A1, mM 1.3760.07 1.4860.05 1.4360.05 1.5160.07 1.2960.04 1.2760.02 1.2860.02 1.2660.03
P-Apo B, mM 0.9460.06(*) 0.8260.04 0.8660.04 0.8460.06 1.0360.04 1.0360.03 1.0360.02 1.0560.06
P-ApoB/A1 0.7260.07* 0.5760.03 0.6360.04 0.5660.04 0.8460.05 0.8260.02 0.8360.02 0.8360.04
Values are mean 6 SE. Significances (by t-test) were only calculated between groups with heredity or not for type 2 diabetes and between groups with heredity or not
for overweight or obesity.
(*)0.05,p,0.1,
*p,0.05,
**p=0.01,
***p,0.001.
doi:10.1371/journal.pone.0018284.t001
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enlarged fat cells predispose for future development of Type 2
diabetes irrespective of BMI [19,20].
The molecular mechanisms for the impaired recruitment and/
or commitment of new subcutaneous preadipocytes in individuals
with a genetic predisposition for Type 2 diabetes are currently
Figure 1. Body fat in relation to adipose cell size. Adipose cell size in relation to body fat in all individuals with (red circles) or without (blue
dots) a known genetic predisposition for Type 2 diabetes (A) or overweight/obesity (B). The figures below display the relationships between fat cell
size and body fat in lean individuals (BMI,25 kg/m
2 with (solid lines) or without (broken lines) a diabetes (C) or overweight/obesity heredity (D).
Significance of differences between the groups in cell size vs body fat was tested with ANCOVA for those with or without diabetes (F=5.8, p=0.019)
(C) or overweight/obesity (F=0.04, p=0.85) (D) heredity.
doi:10.1371/journal.pone.0018284.g001
Figure 2. Insulin sensitivity in relation to adipose cell size. (A) Insulin sensitivity, measured with the euglycemic clamp, in non-obese
individuals (BMI,28 kg/m
2) with a genetic predisposition for Type 2 diabetes in relation mean abdominal adipose cell volume (r=20.39, p,0.0001)
and (B) delta-values (r=0.35, p,0.0001). The results are expressed as mg glucose infused (GIR)/kg lean body mass (LBM) and minute.
doi:10.1371/journal.pone.0018284.g002
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activation and/or the infiltration of macrophages and inflamma-
tion in the adipose tissue. TNFa would appear as an interesting
candidate since it is a powerful inhibitor of differentiation of
human preadipocytes [12] and, in addition, activates Wnt
signaling [21]. In this regard, potential genetic factors would also
include altered activity of molecules cleaving and activating TNFa
like the TNF converting-enzyme [22].
Taken together our findings provide a novel mechanism
whereby a genetic predisposition for Type 2 diabetes makes the
individuals particularly susceptible to the environment and that
even small increases in body fat promote a reduced insulin
sensitivity and a dysmetabolic and proatherogenic phenotype with
an increased risk to develop Type 2 diabetes. Thus, diabetes
heredity is associated with an increased susceptibility to the
environment in terms of becoming ‘‘obese’’ in the adipose tissue
even when they have small amounts of body fat. If this
inappropriate expansion of adipose cell size is related to a reduced
stem cell commitment and/or subsequent differentiation of
committed preadipocytes is unknown but a current focus of study.
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